JPWO2019173744A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173744A5 JPWO2019173744A5 JP2020547139A JP2020547139A JPWO2019173744A5 JP WO2019173744 A5 JPWO2019173744 A5 JP WO2019173744A5 JP 2020547139 A JP2020547139 A JP 2020547139A JP 2020547139 A JP2020547139 A JP 2020547139A JP WO2019173744 A5 JPWO2019173744 A5 JP WO2019173744A5
- Authority
- JP
- Japan
- Prior art keywords
- ocular
- conjunctivitis
- inflammation
- keratitis
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 19
- 206010061218 Inflammation Diseases 0.000 claims 17
- 230000004054 inflammatory process Effects 0.000 claims 17
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 16
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 14
- 206010023332 keratitis Diseases 0.000 claims 13
- 208000022873 Ocular disease Diseases 0.000 claims 12
- 229940125904 compound 1 Drugs 0.000 claims 11
- 210000000744 eyelid Anatomy 0.000 claims 11
- 206010010741 Conjunctivitis Diseases 0.000 claims 10
- 239000000872 buffer Substances 0.000 claims 10
- 210000001508 eye Anatomy 0.000 claims 9
- 235000011187 glycerol Nutrition 0.000 claims 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 6
- 206010013774 Dry eye Diseases 0.000 claims 6
- 206010015150 Erythema Diseases 0.000 claims 6
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000003840 hydrochlorides Chemical class 0.000 claims 6
- 230000001575 pathological effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000008961 swelling Effects 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 5
- 239000008363 phosphate buffer Substances 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 4
- 208000014260 Fungal keratitis Diseases 0.000 claims 4
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 238000004040 coloring Methods 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 208000003251 Pruritus Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 210000005252 bulbus oculi Anatomy 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 208000027744 congestion Diseases 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 230000009545 invasion Effects 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- 230000002980 postoperative effect Effects 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 230000000472 traumatic effect Effects 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 241000909851 Epiphora Species 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- 206010022941 Iridocyclitis Diseases 0.000 claims 2
- 241001420836 Ophthalmitis Species 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 206010042674 Swelling Diseases 0.000 claims 2
- 206010046914 Vaginal infection Diseases 0.000 claims 2
- 201000008100 Vaginitis Diseases 0.000 claims 2
- 201000004612 anterior uveitis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 208000016747 lacrimal apparatus disease Diseases 0.000 claims 2
- 206010069732 neurotrophic keratopathy Diseases 0.000 claims 2
- 208000010403 panophthalmitis Diseases 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 206010015084 Episcleritis Diseases 0.000 claims 1
- 206010052140 Eye pruritus Diseases 0.000 claims 1
- 206010015967 Eye swelling Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000008181 tonicity modifier Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641094P | 2018-03-09 | 2018-03-09 | |
| US62/641,094 | 2018-03-09 | ||
| US201862663999P | 2018-04-27 | 2018-04-27 | |
| US62/663,999 | 2018-04-27 | ||
| PCT/US2019/021402 WO2019173744A1 (en) | 2018-03-09 | 2019-03-08 | Methods of use and pharmaceutical compositions of a selective syk inhibitor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517139A JP2021517139A (ja) | 2021-07-15 |
| JP2021517139A5 JP2021517139A5 (https=) | 2022-03-10 |
| JPWO2019173744A5 true JPWO2019173744A5 (https=) | 2022-03-10 |
| JP7417531B2 JP7417531B2 (ja) | 2024-01-18 |
Family
ID=65818744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547139A Active JP7417531B2 (ja) | 2018-03-09 | 2019-03-08 | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210052582A1 (https=) |
| EP (1) | EP3761986A1 (https=) |
| JP (1) | JP7417531B2 (https=) |
| KR (1) | KR20210018193A (https=) |
| CN (2) | CN112243375A (https=) |
| AU (1) | AU2019230220B2 (https=) |
| BR (1) | BR112020018377A2 (https=) |
| CA (1) | CA3093371A1 (https=) |
| IL (1) | IL277093A (https=) |
| MX (1) | MX2020009396A (https=) |
| PH (1) | PH12020551418A1 (https=) |
| SG (1) | SG11202008765UA (https=) |
| TW (1) | TWI805705B (https=) |
| WO (1) | WO2019173744A1 (https=) |
| ZA (1) | ZA202005459B (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056457A2 (en) * | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| KR101454674B1 (ko) | 2006-03-17 | 2014-10-27 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물 |
| MX2010011463A (es) * | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| SG2014015085A (en) * | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| KR20140103168A (ko) * | 2011-12-16 | 2014-08-25 | 알러간, 인코포레이티드 | 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물 |
| AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| EP2897950A1 (en) * | 2012-09-18 | 2015-07-29 | Ziarco Pharma Ltd | 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors |
-
2019
- 2019-03-08 CN CN201980017916.9A patent/CN112243375A/zh active Pending
- 2019-03-08 TW TW108107933A patent/TWI805705B/zh not_active IP Right Cessation
- 2019-03-08 AU AU2019230220A patent/AU2019230220B2/en active Active
- 2019-03-08 JP JP2020547139A patent/JP7417531B2/ja active Active
- 2019-03-08 EP EP19712475.3A patent/EP3761986A1/en active Pending
- 2019-03-08 KR KR1020207028762A patent/KR20210018193A/ko active Pending
- 2019-03-08 CA CA3093371A patent/CA3093371A1/en active Pending
- 2019-03-08 US US16/979,075 patent/US20210052582A1/en not_active Abandoned
- 2019-03-08 BR BR112020018377-6A patent/BR112020018377A2/pt not_active Application Discontinuation
- 2019-03-08 SG SG11202008765UA patent/SG11202008765UA/en unknown
- 2019-03-08 WO PCT/US2019/021402 patent/WO2019173744A1/en not_active Ceased
- 2019-03-08 CN CN202411182880.9A patent/CN119235862A/zh active Pending
- 2019-03-08 MX MX2020009396A patent/MX2020009396A/es unknown
-
2020
- 2020-09-01 IL IL277093A patent/IL277093A/en unknown
- 2020-09-01 ZA ZA2020/05459A patent/ZA202005459B/en unknown
- 2020-09-09 PH PH12020551418A patent/PH12020551418A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2614838T3 (en) | Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eyes | |
| CA2486910A1 (en) | Ophthalmological use of roflumilast for the treatment of diseases of the eye | |
| JP6163482B2 (ja) | シクロスポリンａの結晶形態、その調製方法、およびその使用のための方法 | |
| US20130190278A1 (en) | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | |
| WO2008053982A1 (en) | Composition for treating allergy | |
| JPWO2020074697A5 (https=) | ||
| CN115103842A (zh) | 用于治疗眼部疾病的组合物 | |
| CN107735091A (zh) | 包含伊马替尼作为活性成分的用于预防和治疗干眼病的药物组合物 | |
| US20120027842A1 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| JP7038437B2 (ja) | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 | |
| US20150099807A1 (en) | Preservative free bimatoprost solutions | |
| AU2006260184A1 (en) | Prophylactic or therapeutic agent for corneal/conjunctival disease | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| JPWO2019173744A5 (https=) | ||
| JP2022529823A (ja) | ドライアイの治療に使用可能な組成物および方法 | |
| WO2016182032A1 (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP2021517139A5 (https=) | ||
| WO2021145355A1 (ja) | 近視の治療、近視の予防および／または近視の進行抑制のための医薬組成物 | |
| JP7417531B2 (ja) | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 | |
| ES2377342T3 (es) | Remedio para enfermedades corneales | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| KR100518276B1 (ko) | 동물의 담즙을 이용한 새로운 안과용 조성물 | |
| US20180221417A1 (en) | Treatment of dry eye using amnion released factors | |
| JPWO2020165838A5 (https=) | ||
| WO2025049378A1 (en) | Netarsudil ophthalmological formulations with less toxicity |